Targets › LILRB2
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.
Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. (UniProt, Q8N423)
Open in Phaseline: the race on LILRB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OncoResponse | OR502 anti-LILRB2 monoclonal antibody | LILRB2 | Phase 1 | Cancer | Feb 2027 |
| SparX Biotech(Jiangsu) Co., Ltd. | SPX-303 Bispecific antibody targeting LILRB2 and PD-L1 | LILRB2, PDCD274 | Phase 1 | Solid Tumor | Sep 2027 |
Solid Tumor (1) Cancer (1)
antibody (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.